COPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2025 financial results.
Evaxion announces business update and third quarter 2025 financial results
Seeking Alpha / 2 hours from now 1 Views
Comments